**Background of IL-7 Antibodies**
Interleukin-7 (IL-7) is a cytokine critical for lymphocyte development, homeostasis, and immune response regulation. It binds to the IL-7 receptor (IL-7R), composed of the IL-7Rα chain (CD127) and the common γ-chain (γc), activating downstream signaling pathways (JAK-STAT, PI3K-AKT, MAPK) that promote T-cell survival, proliferation, and differentiation. Dysregulated IL-7 signaling is implicated in autoimmune diseases, lymphopenia, and cancers, making it a therapeutic target.
IL-7 antibodies are engineered to either block or modulate IL-7/IL-7R interactions. Antagonistic antibodies inhibit IL-7 signaling, potentially treating autoimmune conditions (e.g., multiple sclerosis, rheumatoid arthritis) or preventing graft-versus-host disease. Conversely, agonistic antibodies may enhance IL-7 activity to boost T-cell reconstitution in immunodeficiency (e.g., post-chemotherapy or HIV) or improve antitumor immunity.
Clinical development faces challenges, including balancing efficacy with off-target effects and avoiding cytokine release syndrome. Novel strategies include bispecific antibodies targeting IL-7R and tumor antigens, or combining IL-7 antibodies with checkpoint inhibitors. Research also explores biomarkers (e.g., soluble IL-7R levels) to predict therapeutic response.
Despite preclinical promise, few IL-7 antibodies have reached late-stage trials, underscoring the need for refined targeting approaches. Ongoing studies aim to optimize antibody specificity, half-life, and safety profiles for diverse immunotherapeutic applications.